Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Evotec signs drug discovery agreement with Ono
April 2008
SHARING OPTIONS:

HAMBBURG, GermanyŚEvotec AG, a leader in the discovery and development of novel small molecule drugs, has signed a fragment-based drug discovery agreement with Japanese drug manufacturer Ono Pharmaceutical Co. Ltd. The agreement calls for the use of Evotec's EVOlution platform to identify novel, small molecular weight compounds active against a protease target. The platform integrates protein X-ray crystallography, computational chemistry, structural biology, biochemical and NMR-based fragment screening in combination with Evotec's fragment libraries. Under the agreement, Ono will pay to Evotec initial technology access fees for access to EVOlution, research funding as well as success-based milestones.



 

Back



PAGE UTILITIES


CONTACT US
DDNEWS
478 Bay Street, Suite A213
Midland, Ontario, Canada L4R 1K9
Ph: 888-781-0328 |  Fax: 705-528-0270
 
© Copyright 2020 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.